Altimmune (ALT) Change in Receivables (2010 - 2026)
Altimmune (ALT) posted quarterly Change in Receivables of $446000.0 for Q1 2026, up 1305.41% year-over-year from $31734.6 in Q1 2025, and up 19.25% quarter-over-quarter from $374000.0 in Q4 2025.
Powered by 
Analysis
Altimmune (ALT) Change in Receivables (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Change in Receivables for 17 consecutive years, with $446000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 1305.41% year-over-year to $446000.0; the TTM figure through Mar 2026 stood at $1.2 million (up 479.0% YoY), while the FY2025 annual figure was $675000.0, up 219.05% from the prior year.
- Change in Receivables climbed to $446000.0 in Q1 2026 per ALT's latest filing, from $374000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $741000.0 in Q3 2023 and bottomed at -$804000.0 in Q1 2024.
- Historically, Change in Receivables has averaged $72705.9 across 5 years, with a median of $80000.0 in 2023.
- Annual changes were most pronounced in 2023 — Change in Receivables plunged 4000.0% — and 2025, when it soared 13000.0%.
- Altimmune's Change in Receivables stood at -$460000.0 in 2022, then jumped by 150.87% to $234000.0 in 2023, then plunged by 50.43% to $116000.0 in 2024, then jumped by 222.41% to $374000.0 in 2025, then rose by 19.25% to $446000.0 in 2026.
- Business Quant data shows ALT's Change in Receivables at $446000.0 in Q1 2026, $374000.0 in Q4 2025, and $524000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - | 1.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.68 Mn |
| Mar 31, 2026 | 446,000.00 |
| Dec 31, 2025 | 374,000.00 |
| Sep 30, 2025 | 524,000.00 |
| Jun 30, 2025 | -186,000.00 |
| Mar 31, 2025 | -37,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Sep 30, 2024 | 4,000.00 |
| Jun 30, 2024 | 117,000.00 |
| Mar 31, 2024 | -804,000.00 |
| Dec 31, 2023 | 234,000.00 |
| Sep 30, 2023 | 741,000.00 |
| Jun 30, 2023 | -117,000.00 |
| Mar 31, 2023 | 80,000.00 |
| Dec 31, 2022 | -460,000.00 |
| Sep 30, 2022 | 437,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Mar 31, 2022 | -236,000.00 |
| Dec 31, 2021 | -1.15 Mn |
| Sep 30, 2021 | -3.13 Mn |